No Data
PolyPid Price Target Lowered to $11 From $14 at H.C. Wainwright
PolyPid Down 19% After Study Update, Private Placement
PolyPid Eyes Results From D-PLEX100 Trial in Q2 After Independent Board Gives Nod to Complete Enrollment
Express News | PolyPid Ltd - 630 Patients Enrolled, Completion Expected Q1 2025, Results Q2 2025
Express News | PolyPid Announces Positive Recommendation by Dsmb to Continue Enrollment of Phase 3 Shield II Trial of D-Plex₁₀₀ to 800 Patients With a Concurrent Private Placement of up to $41 Million
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients With a Concurrent Private Placement of up to $41 Million
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
